Frequency, Progression, and Current Management: Report of 16 New Cases of Nonfunctional Pancreatic Neuroendocrine Tumors in Tuberous Sclerosis Complex and Comparison With Previous Reports

Kate Mowrey, Hope Northrup, Peyton Rougeau, S Shahrukh Hashmi, Darcy A Krueger, Daniel Ebrahimi-Fakhari, Alexander J Towbin, Andrew T Trout, Jamie K Capal, David Neal Franz, David Rodriguez-Buritica, Kate Mowrey, Hope Northrup, Peyton Rougeau, S Shahrukh Hashmi, Darcy A Krueger, Daniel Ebrahimi-Fakhari, Alexander J Towbin, Andrew T Trout, Jamie K Capal, David Neal Franz, David Rodriguez-Buritica

Abstract

Background: Tuberous sclerosis complex (TSC) is a genetic condition that causes benign tumors to grow in multiple organ systems. Nonfunctional pancreatic neuroendocrine tumors (PNETs) are a rare clinical feature of TSC with no specific guidelines outlined for clinical management at this time. Our purpose is to calculate the frequency of nonfunctional PNETs as well as characterize the presentation, current clinical management, and assess the impact of systemic mammalian target of rapamycin (mTOR) on nonfunctional PNETs in TSC. Methods: This retrospective chart review was performed by a query of the TS Alliance's Natural History Database and the Cincinnati Children's Hospital TSC Database for patients with nonfunctional PNET. Clinical data from these two groups was summarized for patients identified to have a nonfunctional PNET and compared to previously reported cases with TSC and nonfunctional PNETs. Results: Our calculated frequency of nonfunctional PNETs is 0.65%. We identified 16 individuals, nine males and seven females, with a median age of 18.0 years (interquartile range: -15.5 to 25.5). Just over half (56.3%, n = 9) of the patients provided results from genetic testing. Six had pathogenic variants in TSC2 whereas three had pathogenic variants in TSC1. The average age at PNET diagnosis was 15.0 years (range: 3-46 years). Almost all individuals were diagnosed with a PNET during routine TSC surveillance, 56.3% (n = 9) by MRI, 12.5% (n = 2) by CT, 25% (n = 4) by ultrasound, and 6.2% (n = 1) through a surgical procedure. Follow up after diagnosis involved 68.8% (n = 11) having serial imaging and nine of the sixteen individuals proceeding with surgical removal of the PNET. Eight individuals had a history of using systemic mTOR inhibitors. Tumor growth rate was slightly less in individuals taking an mTOR inhibitor (-0.8 mm/yr, IQR: -2.3 to 2.2) than those without (1.6 mm/yr; IQR: -0.99 to 5.01, p > 0.05). Conclusions: Nonfunctional PNETs occurred at younger ages in our TSC cohort and more commonly compared to ages and prevalence reported for the general population. PNETs in patients on systemic mTOR inhibitors had lower rates of growth. The outcome of this study provides preliminary evidence supporting the use of mTOR inhibitor therapy in conjunction with serial imaging as medical management for nonfunctional PNETs as an alternative option to invasive surgical removal.

Keywords: abdominal imaging; nonfunctional; pancreatic neuroendocrine tumor; surveillance; tuberous sclerosis.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Mowrey, Northrup, Rougeau, Hashmi, Krueger, Ebrahimi-Fakhari, Towbin, Trout, Capal, Franz and Rodriguez-Buritica.

Figures

Figure 1
Figure 1
Study flow chart and patient selection process.
Figure 2
Figure 2
Diameter trend of PNET in subjects from the TS Alliance's Natural History Database and the Cincinnati Children's Hospital TSC Database. Asterisk indicates that Subject 16 started and stopped an mTOR inhibitor therapy between imaging and never had any imaging performed while actively taking an mTOR inhibitor.
Figure 3
Figure 3
(A) [Upper left] Axial T2-weighted fast spin echo and (B) [Upper right] diffusion weighted MRI images performed in a 6-year-old boy show a 1.2 × 0.8 cm hyperintense mass (arrow) in the tail of the pancreas that restricts diffusion. Note that small cysts are also present within the left kidney. (C) [Lower left] an Axial T2-weighted fast spin echo and (D) [Lower right] diffusion weighted MRI images performed 3 years later show that the pancreatic tail mass (arrow) has grown slowly and now measures 1.4 × 1.5 cm.
Figure 4
Figure 4
PNET diameter as a function of age in TSC subjects of the TS Alliance's Natural History Database, the Cincinnati Children's Hospital TSC Database, and previously published cases.

References

    1. Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, von Kries R, Heinrich B, et al. . Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. (2018) 13:1–8. 10.1186/s13023-018-0870-y
    1. Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. (2013) 49:255–65. 10.1016/j.pediatrneurol.2013.08.002
    1. Sancak O, Nellist M, Goedbloed M, Elfferich P, Wouters C, Maat-Kievit A, et al. . Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype-phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. (2005) 13:731–41. 10.1038/sj.ejhg.5201402
    1. The European Chromosome 16 Tuberous Sclerosis Consortium . Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. (1993) 75:1305–15. 10.1016/0092-8674(93)90618-Z
    1. van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. . Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. (1997) 277:805–8. 10.1126/science.277.5327.805
    1. Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. . Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. Genet Med. (2007) 9:88–100. 10.1097/GIM.0b013e31803068c7
    1. Bombardieri R, Moavero R, Roberto D, Cerminara C, Curatolo P. Pancreatic neuroendocrine tumor in a child with a tuberous sclerosis complex 2 (TSC2) mutation. Endocr Pract. (2013) 19:e124–8. 10.4158/
    1. Mortaji P, Morris KT, Samedi V, Eberhardt S, Ryan S. Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature. Familial Cancer. (2018) 17:275–80. 10.1007/s10689-017-0029-3
    1. Koc G, Sugimoto S, Kuperman R, Kammen BF, Karakas SP. Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol. (2017) 47:39–45. 10.1007/s00247-016-3701-0
    1. Mehta S, Rusyn L, Ginsburg H, Hajdu C, Kohn B. Pancreatic neuroendocrine tumor in a young child with tuberous sclerosis complex 1. J Endocr Soc. (2019) 3:1201–6. 10.1210/js.2019-00051
    1. Amarjothi JMV, Jesudason J, Ramasamy V, Babu OLN. Interesting pancreatic tumour in the background of tuberous sclerosis. BMJ Case Rep. (2019) 12:e227292. 10.1136/bcr-2018-227292
    1. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. (2008) 19:1727–33. 10.1093/annonc/mdn351
    1. Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. . The 2019 WHO classification of tumours of the digestive system. Histopathology. (2020) 76:182–8. 10.1111/his.13975
    1. Khanna L, Prasad SR, Sunnapwar A, Kondapaneni S, Dasyam A, Tammisetti VS, et al. . Pancreatic neuroendocrine neo-plasms: 2020 update on pathologic and imaging findings and classification. Radiographics. (2020) 40:1240–62. 10.1148/rg.2020200025
    1. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. (2011) 40:1–18. 10.1016/j.ecl.2010.12.005
    1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. . One hundred years after “carcinoid:” epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. (2008) 26:3063–72. 10.1200/JCO.2007.15.4377
    1. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. (2008) 135:1469–92. 10.1053/j.gastro.2008.05.047
    1. Giusti F, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A. editors. GeneReviews ®. Seattle, WA: University of Washington, Seattle; (2005).
    1. Nishi T, Kawabata Y, Hari Y, Imaoka H, Ishikawa N, Yano S, et al. . A Case of Pancreatic Neuroendocrine Tumor in a Patient with Neurofibromatosis-1. (2012). Available online at: (accessed May 18, 2020).
    1. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. (2008) 113:1807–43. 10.1002/cncr.23648
    1. Alexakis N, Connor S, Ghaneh P, Lombard M, Smart HL, Evans J, et al. . Hereditary pancreatic endocrine tumours. Pancreatology. (2004) 4:417–35. 10.1159/000079616
    1. van Leeuwaarde RS, Pieterman CRC, Bleiker EMA, Dekkers OM, van der Horst-Schrivers AN, Hermus AR, et al. . High fear of disease occurrence is associated with low quality of life in patients with multiple endocrine neoplasia type 1: results from the Dutch MEN1 Study Group. J Clin Endocrinol Metab. (2018) 103:2354–61. 10.1210/jc.2018-00259
    1. Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol. (2015) 11:853–64. 10.2217/fon.14.285
    1. Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. . E-mail ENETS consensus guidelines ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. (2016) 103:153–71. 10.1159/000443171
    1. Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, et al. . Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: The Massachusetts General Hospital experience from 1977 to 2005. Archiv Surg. (2007) 142:347–53. 10.1001/archsurg.142.4.347
    1. Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. (2012) 19:2932–6. 10.1245/s10434-012-2285-7
    1. Kuo JH, Lee JA, Chabot JA. Nonfunctional pancreatic neuroendocrine tumors. Surg Clin North Am. (2014) 94:689–708. 10.1016/j.suc.2014.02.010
    1. Partelli S, Ramage JK, Massironi S, Zerbi A, Kim HB, Niccoli P, et al. . Management of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine neoplasms (ASPEN) ≤2 cm: study protocol for a prospective observational study. Front Med. (2020) 7:598438. 10.3389/fmed.2020.598438
    1. Merritt JL, Davis DME, Pittelkow ME, Babovic-Vuksanovic D. Extensive acrochordons and pancreatic islet-cell tumors in tuberous sclerosis associated with TSC2 mutations. Am J Med Genet Part A. (2006) 140:1669–72. 10.1002/ajmg.a.31351
    1. Francalanci P, Diomedi-Camassei F, Purificato C, Santorelli M, Giannotti A, Dominici C, et al. . Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol. (2003) 27:1386–9. 10.1097/00000478-200310000-00012
    1. Arva NC, Pappas JG, Bhatla T, Raetz EA, Macari M, Ginsburg HB, et al. . Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis–case report and review of the literature. Am J Surg Pathol. (2012) 36:149–53. 10.1097/PAS.0b013e31823d0560
    1. Díaz DD, Ibarrola C, Sanz RG, Hurtado BP, Tabares JS, Ruizdelgado FC. Neuroendocrine tumor of the pancreas in a patient with tuberous sclerosis: A case report and review of the literature. Int J Surg Pathol. (2012) 20:390–5. 10.1177/1066896911428735
    1. van den Akker M, Angelini P, Taylor G, Chami R, Gerstle JT, Gupta A. Malignant pancreatic tumors in children: a single-institution series. J Pediatr Surg. (2012) 47:681–7. 10.1016/j.jpedsurg.2011.11.046
    1. Larson A, Hedgire S, Deshpande V, Stemmer-Rachamimov A, Harisinghani M, Ferrone C, et al. . Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex Nothing to declare. Clin Genet. (2012) 82:558–63. 10.1111/j.1399-0004.2011.01805.x
    1. Ilgren EB, Westmorelandt D. Tuberous sclerosis: unusual associations in four cases. J Clin Pathol. (1984) 37:272–8. 10.1136/jcp.37.3.272
    1. Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, Bax NMA, Ariyurek Y, Hermans CJ, et al. . Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr. (1999) 158:284–7. 10.1007/s004310051073
    1. Dworakowska D, Grossman AB. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. Endocr Relat Cancer. (2009) 16:45–58. 10.1677/ERC-08-0142
    1. Eledrisi MS, Stuart CA, Alshanti M. Insulinoma in a patient with tuberous sclerosis: is there an association? Endocrine Practice. (2002) 8:109–12. 10.4158/ep.8.2.109
    1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. . Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. (2017) 3:1335–42. 10.1001/jamaoncol.2017.0589
    1. de Mestier L, Gaujoux S, Cros J, Hentic O, Vullierme MP, Couvelard A, et al. . Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg. (2015) 262:384–8. 10.1097/SLA.0000000000000856
    1. Sato K, Ueda Y, Tachibana H, Miyazawa K, Chikazawa I, Kaji S, et al. . Malignant epithelioid angiomyolipoma of the kidney in a patient with tuberous sclerosis: an autopsy case report with p53 gene mutation analysis. Pathol Res Pract. (2008) 204:771–7. 10.1016/j.prp.2008.04.008
    1. Thomas-Marques L, Murat A, Delemer B, Penfornis A, Cardot-Bauters C, Baudin E, et al. . Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol. (2006) 101:266–73. 10.1111/j.1572-0241.2006.00367.x
    1. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, et al. . Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg. (2006) 243:265–72. 10.1097/01.sla.0000197715.96762.68
    1. Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, et al. . Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. (2013). Available online at:
    1. Vashi PG, Gupta D, Dahlk S. A unique case of a nonfunctional metastatic pancreatic neuroendocrine tumor transforming into an insulin-secreting tumor with an unusual clinical course. Pancreas. (2011) 40:781–4. 10.1097/MPA.0b013e318212c42d
    1. Koshy AA, Gordon IO, van Ha TG, Kaplan EL, Philipson LH. Metastatic insulinoma following resection of nonsecreting pancreatic islet cell tumor. J Investig Med High Impact Case Rep. (2013) 1:232470961247327. 10.1177/2324709612473274
    1. Nahmias A, Grozinsky-Glasberg S, Salmon A, Gross DJ. Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease. Endocrinol Diabetes Metab Case Rep. (2015) 2015:150032. 10.1530/edm-15-0032
    1. Sayki Arslan M, Ozbek M, Karakose M, Tutal E, Ucan B, Yilmazer D, et al. . Transformation of nonfunctioning pancreatic tumor into malignant insulinoma after 3 years: an uncommon clinical course of insulinoma. Arch Endocrinol Metab. (2015) 59:270–2. 10.1590/2359-3997000000049
    1. Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, et al. . The role of mTOR in neuroendocrine tumors: future cornerstone of a winning strategy? Int J Mol Sci. (2018) 19:747. 10.3390/ijms19030747

Source: PubMed

3
Předplatit